Error disclosure in neonatal intensive care: a multicentre, prospective, observational study.


Journal

BMJ quality & safety
ISSN: 2044-5423
Titre abrégé: BMJ Qual Saf
Pays: England
ID NLM: 101546984

Informations de publication

Date de publication:
10 2023
Historique:
received: 07 06 2022
accepted: 08 11 2022
medline: 21 9 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: ppublish

Résumé

Surveys based on hypothetical situations suggest that health-care providers agree that disclosure of errors and adverse events to patients and families is a professional obligation but do not always disclose them. Disclosure rates and reasons for the choice have not previously been studied. To measure the proportion of errors disclosed by neonatal intensive care unit (NICU) professionals to parents and identify motives for and barriers to disclosure. Prospective, observational study nested in a randomised controlled trial (Study on Preventing Adverse Events in Neonates (SEPREVEN); ClinicalTrials.gov). Event disclosure was not intended to be related to the intervention tested. 10 NICUs in France with a 20-month follow-up, starting November 2015. n=1019 patients with NICU stay ≥2 days with ≥1 error. Characteristics of errors (type, severity, timing of discovery), patients and professionals, self-reported motives for disclosure and non-disclosure. Rate of error disclosure reported anonymously and voluntarily by physicians and nurses; perceived parental reaction to disclosure. Among 1822 errors concerning 1019 patients (mean gestational age: 30.8±4.5 weeks), 752 (41.3%) were disclosed. Independent risk factors for non-disclosure were nighttime discovery of error (OR 2.40; 95% CI 1.75 to 3.30), milder consequence (for moderate consequence: OR 1.85; 95% CI 0.89 to 3.86; no consequence: OR 6.49; 95% CI 2.99 to 14.11), a shorter interval between admission and error, error type and fewer beds. The most frequent reported reasons for non-disclosure were parental absence at its discovery and a perceived lack of serious consequence. In the particular context of the SEPREVEN randomised controlled trial of NICUs, staff did not disclose the majority of errors to parents, especially in the absence of moderate consequence for the infant. NCT02598609.

Identifiants

pubmed: 36918264
pii: bmjqs-2022-015247
doi: 10.1136/bmjqs-2022-015247
doi:

Banques de données

ClinicalTrials.gov
['NCT02598609']

Types de publication

Randomized Controlled Trial Observational Study Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

589-599

Investigateurs

Dominique Astruc (D)
Valérie Biran (V)
Leila Marcus (L)
Laurent Beghin (L)
Bernard Guillois (B)
Radia Remichi (R)
Faiza Harbi (F)
Xavier Durrmeyer (X)
Florence Casagrande (F)
Nolwenn Lesaché (N)
Darina Todorova (D)
Ali Bilal (A)
Damien Olivier (D)
Audrey Reynaud (A)
Cécile Jacquin (C)
Jean-Christophe Roze (JC)
Claude Danan (C)
Fabrice Decobert (F)

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Loïc Passini (L)

Neonatal Intensive care Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Stephane Le Bouedec (S)

Neonatal Intensive Care Unit, CHU Angers, Angers, France.

Gilles Dassieu (G)

Neonatal Intensive care Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Audrey Reynaud (A)

Association SOS Préma, Neuilly sur Seine, France.

Camille Jung (C)

Clinical Research Center, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Marie-Laurence Keller (ML)

Neonatal Intensive care Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Aline Lefebvre (A)

Department of Child and Adolescent Psychiatry, APHP, Paris, France.
Human Genetics and Cognitive Functions, Institut Pasteur, UMR 3571 CNRS, University Paris Diderot, Paris, France.
Child and Adolescent Psychiatry Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Therese Katty (T)

Health Law Manager, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Jean-Marc Baleyte (JM)

Child and Adolescent Psychiatry Creteil, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
Faculty of Health, University Paris Est Creteil, Creteil, France.

Richard Layese (R)

INSERM IMRB, CEpiA Team, University Paris Est Creteil, Creteil, France, Créteil, France.
Unité de Recherche Clinique (URC), Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris APHP, Créteil, France.

Etienne Audureau (E)

INSERM IMRB, CEpiA Team, University Paris Est Creteil, Creteil, France, Créteil, France.
Unité de Recherche Clinique (URC), Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris APHP, Créteil, France.

Laurence Caeymaex (L)

Neonatal Intensive care Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France Laurence.Caeymaex@chicreteil.fr.
Clinical Research Center, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
Faculty of Health, University Paris Est Creteil, Creteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH